Teva Company Profile

What is the competitive landscape for TEVA

TEVA has seven hundred and thirty-six approved drugs.

There are sixty-one US patents protecting TEVA drugs. There are fifty-six tentative approvals on TEVA drugs.

There are eight hundred and eighty-five patent family members on TEVA drugs in forty-seven countries and one thousand one hundred and thirty-four supplementary protection certificates in eighteen countries.

Summary for Teva

International Patents:	885
US Patents:	61
Tradenames:	510
Ingredients:	445
NDAs:	736
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	VANTRELA ER	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	207975-002	Jan 17, 2017		DISCN	Yes	No	9,216,176		Y
Teva	ATENOLOL	atenolol	TABLET;ORAL	074056-003	Jul 19, 2004	AB	RX	No	No
Teva Branded Pharm	URECHOLINE	bethanechol chloride	TABLET;ORAL	006536-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Teva Pharms Usa Inc	POTASSIUM CITRATE	potassium citrate	TABLET, EXTENDED RELEASE;ORAL	209758-001	Mar 5, 2018	AB	RX	No	No
Teva Pharms	PRAZOSIN HYDROCHLORIDE	prazosin hydrochloride	CAPSULE;ORAL	071745-003	Sep 12, 1988	AB	RX	No	No
Teva	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	077488-006	Apr 29, 2013		DISCN	No	No
Teva	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	074132-002	Mar 27, 1995	AB	RX	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	MIRCETTE	desogestrel; ethinyl estradiol	TABLET;ORAL-28	020713-001	Apr 22, 1998	RE35724
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-006	Jul 12, 2019	6,871,646
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-002	May 16, 2006	5,387,612
Teva Womens	ADDERALL 7.5	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-011	Aug 31, 2000	6,384,020*PED
Teva Branded Pharm	LOXITANE C	loxapine hydrochloride	CONCENTRATE;ORAL	017658-001	Approved Prior to Jan 1, 1982	4,049,809
Teva Branded Pharm	SEASONALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021544-001	Sep 5, 2003	5,898,032
Teva	UZEDY	risperidone	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	213586-005	Apr 28, 2023	9,925,268

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	for Injection	3.5 mg/vial		2016-10-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Delayed-release Tablets	20 mg		2015-06-03
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22

International Patents for Teva Drugs

Country	Patent Number	Estimated Expiration
Japan	6302983
European Patent Office	3501584
European Patent Office	3471805
Japan	2017039758
Japan	6138322
European Patent Office	2987523
Israel	223116

Supplementary Protection Certificates for Teva Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	C 2016 011	Romania		PRODUCT NAME: TENOFOVIR ALAFENAMIDA SAU O SARE SAU SOLVAT AL ACESTUIA, IN SPECIAL FUMARAT DE TENOFOVIR ALAFENAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1061/001-002; DATE OF NATIONAL AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1061/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20151119
0325571	C980020	Netherlands		PRODUCT NAME: TOLTERODINE, DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN FYSIOLO GISCH ACCEPTABEL ZUUR, IN HET BIJZONDER TOLTERODINE L-TARTRAAT; NAT. REGISTRATION NO/DATE: RVG 22148, RVG 22149 19980217; FIRST REGISTRATION: SE 13475, 13476 19970905
2768484	2019C/545	Belgium		PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827
2203462	C201430078	Spain		PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894; DATE OF FIRST AUTHORISATION IN EEA: 20140116
0817775	06C0010	France		PRODUCT NAME: ERLOTINIB HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 20050919; FIRST REGISTRATION: LI - 57266 20050321
0245997	C300002	Netherlands		PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
0564409	SPC/GB02/016	United Kingdom		PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Inc
• Teva Pharms Intl

Pharmaceutical Competitive Landscape Analysis: TEVA – Market Position, Strengths & Strategic Insights

Last updated: December 24, 2025

Executive Summary

TEVA Pharmaceutical Industries Ltd. stands as a dominant force within the global generics and specialty medicines sectors, positioning itself as a critical player amid a highly competitive landscape. With an extensive portfolio comprising over 3,500 products spanning generics, specialty medicines, and biosimilars, TEVA’s strategic focus on cost leadership, innovation, and geographic diversification has sustained its market relevance. This report offers a comprehensive analysis of TEVA’s current market position, core strengths, challenges, and future strategic pathways, providing insights crucial for stakeholders, investors, and industry analysts.

Introduction

TEVA has evolved from a regional Israeli pharmaceutical company into a global enterprise with a revenue exceeding $16 billion in 2022, primarily driven by generics (~65%) and specialty medicines (~25%) [1]. Its competitive landscape includes firms like Sandoz, Mylan, Pfizer, Novartis, and emerging biosimilar players, amidst rapid market changes influenced by patent expirations, regulatory shifts, and innovation trajectories.

---

What Is TEVA’s Current Market Position?

Market Share & Revenue Breakdown

Segment	Revenue Share (2022)	Key Products	Regional Presence
Generics	65%	Metoprolol, Omeprazole, Pantoprazole	North America, Europe, Asia-Pacific
Specialty Medicines	25%	Austedo, Ajovy, Teva’s biosimilars	North America, Europe
Branded & OTC Filings	10%	Certain proprietary brands	Israel, emerging markets

Source: TEVA Annual Report 2022 [1]

Global Positioning & Competitive Ranking

TEVA ranks among the top 10 global pharmaceutical companies by revenue, notably excelling in the generics space. Its global market position is reinforced by the following:

• Number of Markets: Over 60 countries, with significant footholds in North America (especially the U.S.) and Europe.
• Market Penetration: Estimated at 8-10% share in the US generics market, making it a substantial player.

Key Competitive Advantages

• Extensive Product Portfolio: Wide-ranging offerings reduce dependency on individual product success.
• Cost Leadership: Economies of scale and manufacturing efficiencies facilitate competitive pricing.
• Robust Supply Chain: Worldwide manufacturing footprint enhances supply resilience.

What Are TEVA’s Core Strengths?

1. Product Diversification and Portfolio Breadth

TEVA’s extensive portfolio buffers against market volatility, efforts to innovate selectively in biosimilars and specialty drugs, and timely patent expirations management.

2. Cost Optimization & Manufacturing Scale

With approximately 50 manufacturing facilities globally, TEVA’s cost structure enables aggressive pricing strategies, critical for competing with other generics companies.

3. Geographic Diversification

Strong revenue streams from North America (50%), Europe (30%), and ROW (20%) provide risk mitigation amid regional regulatory or legal issues.

4. Focus on Biosimilars and Specialty Drugs

TEVA’s investment in biosimilars (e.g., Truxima, Semglee) positions it for future growth as biologics treatment markets expand [2].

5. Strategic Acquisitions & Alliances

Recent acquisitions like the acquisition of the Setodine biosimilar portfolio from Samsung Bioepis augment its biologics pipeline.

---

What Challenges and Risks Is TEVA Facing?

1. Patent Cliff and Price Pressures

Numerous key drugs have faced patent expiry, intensifying competition and lowering margins.

2. Legal & Regulatory Risks

Litigations relating to patent disputes and pricing investigations (e.g., U.S. Department of Justice probes) threaten reputation and profitability.

3. Debt and Financial Stability

Post-2016 debt restructuring and the $3.75 billion debt incurred for acquisitions pose financial strain.

4. Supply Chain & Manufacturing Risks

Any disruption due to geopolitical issues or pandemic-related constraints could hamper supply.

---

Strategic Insights: Future Growth Pathways for TEVA

Strategic Area	Initiatives & Opportunities	Potential Impact
Expansion in Biosimilars	Accelerate biosimilar pipeline (e.g., reiterating focus on high-margin biologics)	Position as a biosimilar leader, capturing newmarket segments.
Portfolio Optimization	Divest non-core assets, focusing on high-growth segments	Improve profitability and operational efficiency.
Geographic Expansion	Deepen market penetration in Asia-Pacific and Latin America	Diversify revenue sources, mitigate US market pressures.
Digital Transformation	Leverage AI and analytics for R&D, manufacturing, supply chain	Increase operational efficiencies, reduce costs.

Key Areas of Investment & Innovation

• Biosimilar markets projected to reach $35 billion globally by 2026, growing at 23% CAGR [3].
• Specialty drugs are anticipated to account for 48% of global pharma sales by 2027 [4].

---

Comparison with Peers

Aspect	TEVA	Sandoz (Novartis)	Mylan (Now Viatris)	Pfizer (Generics & Biosimilars)
Revenue (2022)	~$16.4 billion	~$11 billion	~$17 billion	~$54 billion (total)
Core Strengths	Cost leadership, broad portfolio	Biosimilar innovation, diversification	Price competitiveness, manufacturing	Brand portfolio, R&D pipeline
Market Focus	Generics, biosimilars, specialty	Biosimilars, generics, OTC	Generics, biosimilars	Innovative medicines, vaccines

Sources: Company Annual Reports [1], [2], [3], [4]

---

FAQs

Q1: How does TEVA differentiate itself amid intense generic competition?
TEVA leverages its extensive manufacturing scale, cost efficiency, and diversified portfolio to sustain margins. Its focus on biosimilars and specialty drugs also enables entry into higher-margin markets.

Q2: What impact do patent expirations have on TEVA?
Patent cliffs lead to revenue declines in key products; however, TEVA mitigates this by expanding biosimilar offerings and diversifying its product pipeline.

Q3: How is TEVA positioning itself in biosimilars?
TEVA is investing in biosimilar manufacturing with FDA and EMA approvals for drugs like Semglee (insulin glargine) and Truxima (rituximab), aiming to become a biosimilars leader globally.

Q4: What risks does TEVA face in its expansion strategy?
Legal litigations, regulatory challenges, debt levels, and supply chain vulnerabilities pose risks to TEVA's strategic growth plans.

Q5: How does TEVA compare financially to its peers?
While TEVA’s revenue is significant, competitors like Pfizer and Novartis report higher overall sales. Nonetheless, TEVA remains competitive within the generics segment, especially concerning cost management.

---

Key Takeaways

• Leadership Position: TEVA remains one of the top generics companies globally, with strategic diversification into biosimilars and specialty medicines.
• Strengths: Extensive product portfolio, cost efficiencies, geographic diversification, and focus on biosimilar innovation.
• Challenges: Patent expiries, legal risks, high debt levels, and supply chain vulnerabilities require vigilant management.
• Growth Opportunities: Biosimilars market expansion, geographic penetration, and digital transformation are essential for future growth.
• Competitive Edge: Cost leadership complemented by innovation in specialty segments positions TEVA as a resilient player amid industry shifts.

---

References

[1] TEVA Pharmaceuticals Annual Report 2022.
[2] Sandoz Corporate Website. Biosimilars Portfolio.
[3] Grand View Research. Biosimilars Market Size & Growth. 2022.
[4] IQVIA Institute. The Global Use of Medicines 2022.

---

This analysis provides a comprehensive view of TEVA’s market standing, core competencies, and strategic trajectory, empowering industry stakeholders to make informed decisions.